Everything below concerns hGH fragment. We keep the language plain, cite what the science says, and separate well-supported claims from open questions.
Updated 2025-09-18. Numbers and descriptions here follow the published literature rather than marketing material.
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
AOD-9604 is a synthetic peptide whose sequence is modeled on the C-terminal region of human growth hormone. Published descriptions commonly place it as a modified fragment corresponding to hGH amino acids 176–191, with a tyrosine residue added or retained at the N-terminus to support detection and handling. It is not intact growth hormone and lacks the full receptor-binding architecture of the parent protein. The molecule was developed as a research candidate for metabolic studies rather than as a replacement for growth hormone therapy. Its identity is defined by its amino acid sequence rather than by any single commercial preparation.
Commercial AOD-9604 may vary in purity, counterion content, and residual moisture. Certificates of analysis often report HPLC purity, mass confirmation, and appearance, but testing methods differ between suppliers. Independent verification is sometimes used because labeled content may not match actual peptide amount. Stability under different pH and temperature conditions is not fully standardized across studies. Researchers generally treat lyophilized material as the reference form for weighing and reconstitution. Moisture content can affect accurate mass measurement.
AOD-9604 is typically supplied as a lyophilized white to off-white powder. In this form, it is relatively stable when kept cool, dry, and protected from light. Common storage recommendations place it at −20 °C or below for long-term retention. Reconstituted solutions are less stable and are often kept at 2–8 °C for short periods. Freeze-thaw cycles should be minimized because they can promote aggregation or loss of peptide content. Vials are usually sealed under inert gas to reduce oxidation.
Identity and purity are commonly checked with reversed-phase high-performance liquid chromatography and mass spectrometry. RP-HPLC separates the peptide from related impurities and can estimate purity by peak area. Mass spectrometry confirms molecular mass and helps detect sequence variants or truncations. Some laboratories use amino acid analysis or peptide mapping for additional characterization. No single method proves biological activity; these techniques establish chemical identity and purity only. They also require suitable reference standards for confident comparison.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Synthetic peptide | Fragment analog of human growth hormone |
| Sequence basis | hGH 176–191 region | Modified C-terminal fragment |
| Common synonyms | AOD-9604; AOD9604; hGH fragment | Research and trade names vary |
| Regulatory status | Not approved as a drug | Prohibited in competitive sport |
| Research code | AOD9604 | Used in scientific and patent literature |
Researchers have studied the fragment in cell and animal models to understand its metabolic actions. Some experiments report effects on fat breakdown and fat storage pathways, but the underlying mechanism remains incompletely defined. AOD-9604 does not appear to stimulate the same broad growth hormone receptor signaling as full-length hGH. Whether its observed activities arise from direct receptor interactions or downstream metabolic changes is an open question. Results from different assays are not always consistent.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It corresponds to residues 176-191 of the 191-amino-acid hGH sequence. The fragment is not the full hormone and lacks the receptor-binding region associated with growth and metabolic effects of hGH. Researchers developed it to isolate a specific portion of hGH for study. Its exact sequence and length are often stated in peptide catalogs and patents.
Regulatory treatment of AOD-9604 has varied. In sports anti-doping, the peptide became widely discussed during a 2013 investigation into an Australian professional sports club. Authorities at the time debated whether it fell under prohibitions on growth hormone and related substances. Later clarifications and updated lists have addressed the compound in different ways. Anyone seeking current status should consult the latest applicable rules, and commercial supply for human use is not authorized in major markets.
Research interest in AOD-9604 often focuses on whether it can influence lipid metabolism without the growth-promoting or glucose-related effects of full-length hGH. This question remains unresolved, and findings depend on model, dose, and measurement method. Some reviews treat the peptide as a historical obesity candidate rather than an active therapeutic. Others cite it in discussions of peptide fragments, metabolic signaling, and performance-enhancing substances. Clear conclusions are limited by the small number of rigorous, independent human studies.
AOD-9604 has been investigated primarily as a potential treatment for obesity and related metabolic conditions. Early laboratory work examined its effects on fat cells, and later studies moved into animal models and human clinical trials. Some trials reportedly reached Phase II, but the program did not lead to an approved medicine. Published summaries often note that weight-loss results were modest or inconsistent. The full trial data are not all publicly available in detail.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
Microbial growth and proliferation can be inhibited by a technique called biopreservation. Biopreservation is achieved by adding antimicrobials or by increasing the acidity of the fish muscle. Most bacteria stop multiplying when the pH is less than 4.5. Acidity is increased by fermentation, marination or by directly adding acids (acetic, citric, lactic) to fish products. Lactic acid bacteria produce the antimicrobial nisin which further enhances preservation. Other preservatives include nitrites, sulfites, sorbates, benzoates and essential oils.
=== Pollution remediation === NASA's microencapsulating technology enabled the creation of "Petroleum Remediation Product," (PRP) which safely cleans petroleum-based pollutants from water. PRP uses thousands of microcapsules—tiny balls of beeswax with hollow centers. Water cannot penetrate the microcapsule's cell, but oil is absorbed into the beeswax spheres as they float on the water's surface. Contaminating chemical compounds that originally come from crude oil (such as fuels, motor oils, or petroleum hydrocarbons) are caught before they settle, limiting damage to ocean beds. PRP microcapsules serve as nutrients to assist naturally occurring microbes in soil or water to biodegrade contaminants.
The Trump administration blamed Congress for the atrocity and labelled the change in policy as "the Democrats' law", even though Congress had been overwhelmingly dominated by Republicans since 2016. Regardless, members of both parties criticised the policy, and detractors of the Trump administration emphasise that there does not seem to be any written law requiring the government to implement such a policy. Attorney General Jeff Sessions, in defending the policy, quoted a passage from the Bible, even though religious doctrine carries absolutely no weight in American law. Other officials praised the policy as a deterrent to unlawful immigration. The costs of separating migrant children from their parents and keeping them in "tent cities" are higher than keeping them with their parents in detention centres. To handle the large amount of immigration charges brought by the Trump administration, federal prosecutors had to divert resources from other crime cases. It costs $775 per person per night to house the children when they are separated but $256 per person per night when they are held in permanent HHS facilities and $298 per person per night to keep the children with their parents in immigration detention centres. The head of the Justice Department's major crimes unit in San Diego diverted staff from drug smuggling cases. Drug smuggling cases were also increasingly pursued in state courts rather than federal courts, as federal prosecutors were increasingly preoccupied with pursuing charges against illegal border crossings.
== Background == In traditional drug delivery systems such as oral ingestion or intravascular injection, the medication is distributed throughout the body through the systemic blood circulation. For most therapeutic agents, only a small portion of the medication reaches the organ to be affected, such as in chemotherapy where roughly 99% of the drugs administered do not reach the tumor site. Targeted drug delivery seeks to concentrate the medication in the tissues of interest while reducing the relative concentration of the medication in the remaining tissues. For example, by avoiding the host's defense mechanisms and inhibiting non-specific distribution in the liver and spleen, a system can reach the intended site of action in higher concentrations. Targeted delivery is believed to improve efficacy while reducing side-effects. When implementing a targeted release system, the following design criteria for the system must be taken into account: the drug properties, side-effects of the drugs, the route taken for the delivery of the drug, the targeted site, and the disease. Increasing developments to novel treatments requires a controlled microenvironment that is accomplished only through the implementation of therapeutic agents whose side-effects can be avoided with targeted drug delivery. Advances in the field of targeted drug delivery to cardiac tissue will be an integral component to regenerate cardiac tissue.
== Career in industry == Between the year 1947 and 1969, Beynon was Manager of Physics and Physical, Polymer and Analytical Chemistry at Imperial Chemical Industries. Between 1947 and 1950, Beynon constructed what was to become the first mass spectrometer designed to study organic compounds unrelated to petroleum. He subsequently collaborated with Metropolitan-Vickers to produce the MS8 mass spectrometer, a prototype of the Associated Electrical Industries (AEI) MS9 mass spectrometer. Beynon was made a senior research associate in 1964 which allowed him the opportunity to carry out his own research. He was a Boomer Memorial Fellow at the University of Minnesota in 1965.
Sources: en.wikipedia.org
== Sequels == Half-Life 2 was followed by the episodic sequels Episode One (2006) and Episode Two (2007). After canceling Episode Three and several further Half-Life projects, Valve released a prequel, Half-Life: Alyx, in 2020.
Valproic acid has a black box warning for hepatotoxicity, pancreatitis, and fetal abnormalities. There is evidence that valproic acid may cause premature growth plate ossification in children and adolescents, resulting in decreased height. Valproic acid can also cause mydriasis, a dilation of the pupils. There is evidence that shows valproic acid may increase the chance of Polyendocrine metabolic ovarian syndrome (PMOS) in women with epilepsy or bipolar disorder. Studies have shown this risk of PMOS is higher in women with epilepsy compared to those with bipolar disorder. Weight gain is also possible. Valproic acid may decrease platelets in proportion to its dosage, particularly in women and the elderly.
==== Third wave ==== On April 9, 2021, Ford received his first dose of the AstraZeneca COVID-19 vaccine at a local pharmacy in Toronto, and encouraged eligible Ontarians to get vaccinated. Amid growing case numbers in mid-2021, the government moved to introduce a third province-wide stay-at-home order. As part of the response, Ford announced on April 16, 2021, that outdoor amenities including playgrounds would be closed, and that he would be authorizing police to require pedestrians and drivers to explain why they are not at home and provide their home address and other relevant details. The regulations raised concerns about a re-legalization of carding. The government experienced significant backlash with the new enforcement measures, with some commentators – such as the National Post's Randall Denley, a former PC politician – equating the province to a "police state" Members of the Ontario COVID-19 Science Table described the new restrictions as "absolute madness", and not based on science questioning the need to restrict "safe options from people as you do nothing to impact the places where the disease is spreading". After dozens of police services across the province announced that they would refuse to enforce the new measures, Ford promptly rolled back the new enforcement provisions the next day and reopened playgrounds, while keeping other outdoor amenities closed.
The cancerous skin lesions refer to damaged cutaneous tissues with risks of further developing into skin cell carcinoma. Skin carcinoma, or skin cancer, is very common in sun-radiation-abundant areas. The over-exposure to sunlight is the most prevalent cause that leads to Actinic keratosis (AK), a common cancerous cutaneous lesion. Photodynamic therapy (PDT) has proven to be an effective approach for AK at sites of poor healing with few responses to other therapies. In the comparison study between MAL-LEDT and typical cryotherapy, blue-light LEDT with Aminolevulinic acid (ALA) as a photosensitizer reveals significantly higher healing rates. The other clinical trial illustrates the effect of combined therapy of red-light LEDT and nano-emulsion in treating cancerous skin lesions.
Freezing is an effective form of food preservation because the pathogens that cause food spoilage are either killed or do not grow very rapidly at reduced temperatures. The process is less effective in food preservation than are thermal techniques, such as boiling, because pathogens are more likely to be able to survive cold temperatures rather than hot temperatures. One of the problems surrounding the use of freezing as a method of food preservation is the danger that pathogens deactivated (but not killed) by the process will once again become active when the frozen food thaws. Foods may be preserved for several months by freezing. Long-term frozen storage requires a constant temperature of −18 °C (0 °F) or less.
Sources: en.wikipedia.org
=== Morphological instabilities === In an ideal world, the spatial concentration of particles within the SSZ would remain constant throughout solidification. As it happens, though, the concentration of particles does change during compression, and this process is highly sensitive to solidification speed. At low freezing rates, Brownian motion takes place, allowing particles to move easily away from the solid-liquid interface and maintain a homogeneous suspension. In this situation, the suspension is always warmer than the solidified portion. At fast solidification speeds, approaching VC, the concentration, and concentration gradient at the solid-liquid interface increases because particles cannot redistribute soon enough. When it has built up enough, the freezing point of the suspension is below the temperature gradient in the solution and morphological instabilities can occur. For situations where the particle concentration bleeds into the diffusion layer, both the actual and freezing temperature dip below the equilibrium freezing temperature creating an unstable system. Often, these situations lead to the formation of what are known as ice lenses. These morphological instabilities can trap particles, preventing full redistribution and resulting in inhomogeneous distribution of solids along the freezing direction as well as discontinuities in the ceramic walls, creating voids larger than intrinsic pores within the walls of the porous ceramic.
== Absorption and metabolism == NMNH has proven to be a more effective NAD+ enhancer than NMN, achieving a 5-fold increase in NAD+ levels and sustaining elevated levels for six hours while maintaining high levels for up to 24 hours. NMNH treatment leads to a similar trend in NAD+ and NADH biosynthesis as NMN treatment, implying a shared pathway. However, NMNH was shown to inhibit the endogenous synthesis of NMN by blocking the action of nicotinamide phosphoribosyl transferase (NAMPT) This inhibition suggests that NMNH may be more effective than NMN in directly stimulating NAD+ production.
turgor pressure Also turgidity. The force within a cell which pushes the plasma membrane against the cell wall, a type of hydrostatic pressure influenced by the osmotic flow of water into and out of the cell. Turgidity is observed in plants, fungi, bacteria, and some protists with cell walls, but generally not in animal cells.
Canada (1974) Australia (1981) Israel (1983) UK (1987) Netherlands (2010) In 2012, JDF changed its name to Juvenile Diabetes Research Foundation, which was later shortened to JDRF. In 2019, JDRF International appointed its first-ever CEO and president with type 1 diabetes, Dr. Aaron Kowalski. In 2024, the international chapters of the organization began to change their name from JDRF to Breakthrough T1D, reflecting its focus on helping people of all ages and in line with growing awareness that T1D affects people of all ages. The Australian affiliate was the last to change their name on March 31, 2025.
Sources: en.wikipedia.org
No. It is a synthetic peptide fragment modeled on part of human growth hormone, not the full hormone. It does not contain the complete sequence or receptor-binding regions of hGH.
It was investigated in clinical trials for obesity, but it did not receive approval for that use in major markets. Results were generally modest or mixed, and it remains an experimental compound.
WADA lists it as a prohibited peptide hormone. Its use can be detected by laboratory methods, and athletes are subject to sanctions if it is found in samples.
Lyophilized powder is commonly stored at −20 °C or below, protected from light and moisture. Reconstituted solutions are typically kept refrigerated and used within a limited period.